Candel Therapeutics (NASDAQ:CADL – Get Free Report) had its price objective reduced by equities research analysts at Citigroup from $26.00 to $20.00 in a report issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup‘s price objective would indicate a potential upside of 228.41% from the company’s current price.
A number of other analysts have also recently issued reports on the company. Zacks Research cut Candel Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. UBS Group reissued a “buy” rating on shares of Candel Therapeutics in a research note on Monday, August 17th. HC Wainwright cut their price objective on shares of Candel Therapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday. Jefferies Financial Group began coverage on shares of Candel Therapeutics in a research note on Thursday, October 22nd. They issued a “buy” rating and a $25.00 price objective on the stock. Finally, Wall Street Zen cut Candel Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Nine equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $18.29.
Check Out Our Latest Research Report on Candel Therapeutics
Candel Therapeutics Stock Down 1.8%
CADL stock traded down $0.11 during mid-day trading on Monday, hitting $6.09. 1,996,615 shares of the company were exchanged, compared to its average volume of 1,451,537. The firm’s 50 day simple moving average is $9.75 and its 200 day simple moving average is $8.39. Candel Therapeutics has a 1-year low of $4.35 and a 1-year high of $14.00. The firm has a market cap of $466.00 million, a P/E ratio of -4.06 and a beta of -0.27. The company has a debt-to-equity ratio of 0.37, a quick ratio of 7.57 and a current ratio of 7.57.
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.06. On average, sell-side analysts predict that Candel Therapeutics will post -1.29 EPS for the current fiscal year.
Hedge Funds Weigh In On Candel Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Candel Therapeutics during the 3rd quarter valued at $41,000. Legal & General Group Plc acquired a new stake in Candel Therapeutics during the second quarter worth about $63,000. Cetera Investment Advisers acquired a new position in shares of Candel Therapeutics in the 3rd quarter valued at about $124,000. Renaissance Technologies LLC purchased a new stake in shares of Candel Therapeutics during the 1st quarter worth about $63,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Candel Therapeutics by 19.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,962 shares of the company’s stock worth $152,000 after purchasing an additional 2,301 shares during the period. 13.93% of the stock is owned by institutional investors and hedge funds.
About Candel Therapeutics
Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.
Recommended Stories
- Five stocks we like better than Candel Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
